0001293310 false 0001293310 2022-08-31 2022-08-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

 CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 31, 2022 

 

 

 

Humanigen, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware
(State or other Jurisdiction of
Incorporation)

001-35798

(Commission File No.)

77-0557236

(IRS Employer Identification No.)

 

830 Morris Turnpike, 4th Floor

Short Hills, New Jersey 07078
(Address of principal executive offices and zip code)

 

(973) 200-3010
(Registrant's telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

 Name of each exchange on which
registered
Common Stock HGEN The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company     ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

 

 

   
 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 31, 2022, Dr. Adrian Kilcoyne informed Humanigen, Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company, effective September 28, 2022. The Company thanks Dr. Kilcoyne for his contributions and wishes him the best in his future endeavors.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit

No.

   Description
   
104   Cover Page Interactive Data File (embedded within Inline XBRL document).

 

   
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  HUMANIGEN, INC.   
        
Dated: September 2, 2022 By:  /s/ Cameron Durrant   
       
  Name:           Cameron Durrant
  Title:       Chairman of the Board and Chief Executive Officer

 

 

 

 

 

 

 

Humanigen (NASDAQ:HGEN)
Graphique Historique de l'Action
De Mar 2025 à Avr 2025 Plus de graphiques de la Bourse Humanigen
Humanigen (NASDAQ:HGEN)
Graphique Historique de l'Action
De Avr 2024 à Avr 2025 Plus de graphiques de la Bourse Humanigen